Neuroblastoma is a cancer of the sympathetic nervous system that arises most often in the adrenal glands or along the spine, and it accounts for a disproportionate share of childhood cancer deaths. The girl at the center of this report carried one of the worst prognostic markers in the disease: amplification of the MYCN gene, a genetic signature associated with aggressive, treatment-resistant tumors. Her initial treatment followed the standard European induction protocol known as COJEC, a rapid cycle of cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide, followed by two courses of topotecan, vincristine, and doxorubicin. When doctors re-evaluated her disease, the news was grim. The primary tumor in her abdomen remained large and active, it pressed on critical blood vessels, and scans revealed widespread involvement of her bones and bone marrow, yielding a skeletal disease score of 45 on the SIOPEN scale used across European pediatric oncology centers.

What followed was a relentless escalation of therapy. Second-line chemotherapy with temozolomide and irinotecan, later combined with the anti-GD2 antibody dinutuximab beta, succeeded in clearing the metastatic disease from her bones and marrow. She then underwent consolidation with two rounds of radiometabolic therapy using iodine-131 labeled MIBG—a radioactive form of the same tracer molecule used to image neuroblastoma—each followed by reinfusion of her own stem cells, and finally high-dose chemotherapy with busulfan and melphalan supported by another stem-cell rescue. Yet when the dust settled, one enemy remained entrenched: a residual mass in her retroperitoneum, the space behind the abdominal organs, measuring 13.3 by 9.8 by 6.9 centimeters. The mass continued to light up on MIBG scans, proof that living neuroblastoma cells persisted within it, and it wrapped around the celiac artery and the right renal artery while compressing the inferior vena cava, the largest vein in the body.

This anatomical situation presented surgeons with an impossible calculus. Any attempt at resection risked catastrophic hemorrhage from vessels that the tumor had encased, and there was no guarantee that a complete removal could be achieved even at that price. A biopsy taken through the skin confirmed that the mass contained viable neuroblastoma tissue showing differentiating features, meaning the cells were still alive and capable of regrowth. It was at this impasse that a multidisciplinary tumor board—bringing together pediatric oncologists, surgeons, interventional radiologists, pathologists, and radiation therapists at Bambino Gesù Children’s Hospital in Rome—turned to a technique that had never before been applied to a child with this disease: percutaneous electrochemotherapy.

The principle behind electrochemotherapy is elegantly physical. Cell membranes, though thin, are formidable barriers that normally prevent many chemotherapy drugs from entering cells efficiently. When short, high-voltage electric pulses are applied across a tissue, they transiently reorganize the lipid bilayer of those membranes, opening nanoscale pores in a process called reversible electroporation. The pores allow drug molecules to flood into the cell interior, and because the pulses are calibrated carefully, the membranes reseal afterward and the cells survive—only to be killed by the chemotherapy they have now absorbed in quantities far beyond what ordinary exposure could achieve. The drugs most commonly paired with electroporation are bleomycin and cisplatin, both of which become dramatically more cytotoxic inside electroporated cells. In adults, the technique has earned validated roles against melanoma, sarcoma, and head and neck tumors, but pediatric experience has been almost nonexistent.

The Roman team tailored the procedure to the unique biology of neuroblastoma. Rather than administering cisplatin intravenously, they injected it directly into the tumor, a strategy designed to maximize drug concentration within the lesion while minimizing systemic side effects—a rational choice given that platinum compounds are among the drugs to which neuroblastoma is classically sensitive. Under general anesthesia, with the child positioned prone, three variable-geometry needle electrodes with an active length of three centimeters were inserted intercostally, between the ribs, using computed tomography and ultrasound guidance. The target was the most metabolically active portion of the mass, precisely the region where MIBG single-photon emission imaging had shown the greatest tracer uptake and where the tumor pressed hardest against the inferior vena cava. Once the electrodes bracketed the target, an 18-gauge coaxial biopsy was taken through the field, and four milligrams of cisplatin at a concentration of two milligrams per milliliter were injected through a Chiba needle. The Cliniporator VITAE device then delivered voltage pulses ranging from 900 to 1,700 volts, completing the session.

The technical choreography matters because electroporation is unforgiving of sloppy planning. The electric field must cover the entire tumor volume homogeneously; any region that falls between electrodes may receive sub-lethal exposure and survive as a seed of recurrence. This is why careful pre-treatment planning and meticulous electrode placement are considered the linchpins of the technique, particularly for large or irregularly shaped lesions like the one in this case. Encouragingly, the procedure itself was uneventful. No immediate or delayed complications occurred, post-procedure monitoring revealed nothing concerning, and the child was discharged in stable condition. The team notes that the approach is also repeatable, an important attribute for a disease where residual lesions sometimes require more than one local intervention.

The follow-up imaging tells the story in two snapshots. One month after the procedure, magnetic resonance imaging revealed a necrotic, liquefied area of 20 by 20 millimeters within the treated field—direct evidence that the electroporated cells had died on schedule, consistent with the six-to-eight-week window in which electrochemotherapy’s radiological effects typically become apparent. The child then completed her maintenance phase of treatment with cis-retinoic acid and dinutuximab beta without any complications. Twelve months after the procedure, computed tomography and MIBG imaging delivered the decisive verdict: the mass had shrunk to 9.2 by 8.9 by 9.4 centimeters, and, critically, no residual MIBG uptake could be detected anywhere in the treated area. The metabolically active component that had survived everything modern pediatric oncology could throw at it had been silenced.

Why does the disappearance of MIBG avidity matter so much? MIBG is a norepinephrine analog that is taken up specifically by neuroblastoma cells, so persistent tracer uptake is a molecular signature of living tumor. In neuroblastoma, residual primary disease that remains MIBG-avid after multimodal treatment is a well-established negative prognostic factor, strongly correlated with relapse and poor survival. The ability to selectively target and neutralize these metabolically active foci—without opening the abdomen, without thermal energy that could damage vessels and adjacent organs, and without adding systemic toxicity—addresses one of the most frustrating gaps in current therapy. Thermal ablation techniques such as radiofrequency ablation and cryoablation have been used in selected pediatric tumors, but they are hazardous near major vessels, which act as heat sinks and limit ablation margins, and near structures like the celiac artery that cannot tolerate thermal injury. Electrochemotherapy’s non-thermal mechanism sidesteps that constraint, and the authors note that its effects are applicable across tumor histologies, including tumors resistant to other modalities.

The caveats are as important as the promise. This is a single case, reported by the team of Giulia Cassanelli, Maria Antonietta De Ioris, and Gian Luigi Natali, and pediatric oncology is littered with promising one-patient results that failed to generalize. The authors themselves are careful, framing electrochemotherapy as a feasible local option for selected patients and calling for further evaluation within a multidisciplinary framework rather than declaring a new standard of care. Yet the signals here are hard to dismiss: a first-in-child application performed safely in one of the most anatomically hostile locations imaginable, durable local control of the exact tumor component that predicts relapse, and a treatment that can be repeated if needed. If larger studies confirm these findings, children with refractory neuroblastoma whose tumors are deemed inoperable may one day have an option that today they lack entirely—a minimally invasive, precisely targeted way to finish what chemotherapy, antibodies, and radiation started.

Subject of Research: Electrochemotherapy for residual MIBG-avid disease in refractory pediatric neuroblastoma

Article Title: Electrochemotherapy as a potential local treatment for residual MIBG-avid disease in refractory pediatric neuroblastoma: a case report

Article References: Cassanelli, G., De Ioris, M. A., & Natali, G. L. (2026). Electrochemotherapy as a potential local treatment for residual MIBG-avid disease in refractory pediatric neuroblastoma: a case report. CVIR Oncology, 2(1), Article 3. https://doi.org/10.1007/s44343-026-00032-8

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00032-8

Keywords: neuroblastoma, electrochemotherapy, electroporation, cisplatin, pediatric oncology, interventional radiology, MIBG imaging, tumor ablation, MYCN amplification, residual disease, case report, local therapy

Plasmids are circular pieces of DNA that can be engineered to carry therapeutic genes into cells. Unlike viral vectors, which have dominated gene therapy because of their efficiency at transferring genetic material, plasmids are comparatively simple to manufacture, can carry larger payloads, and tend to raise fewer safety concerns related to insertional mutagenesis or uncontrolled viral replication. Their principal limitation has always been delivery: naked DNA does not readily cross cell membranes, and achieving clinically meaningful levels of gene expression inside tumors without a viral carrier has proven challenging. The new research addresses this obstacle by pairing an optimized plasmid combination with an intratumoral delivery approach, injecting the therapeutic construct directly into accessible lesions so that high local concentrations of the encoded proteins are produced precisely where they are needed most.

The therapeutic logic behind intratumoral plasmid delivery rests on a concept that has reshaped modern cancer immunotherapy: the idea that a tumor can be converted from a site of immune evasion into the equivalent of an in situ vaccine. When immune-stimulating genes are expressed inside a tumor, dying cancer cells release tumor antigens together with danger signals, and dendritic cells that traffic through the injected lesion can capture these antigens and carry them to draining lymph nodes. There, T cells are primed against the specific mutations and proteins of that patient’s cancer. Because melanoma is among the most mutationally dense of all human tumors, it presents a rich array of neoantigens, making it a particularly suitable candidate for this kind of localized priming strategy. Once activated, T cells can circulate through the bloodstream and attack metastatic deposits far removed from the injection site, a systemic effect commonly described as an abscopal response.

The combination described in the study was designed so that each plasmid component contributes a complementary function to this immunological cascade. One element is intended to drive the production of immune-activating cytokines within the tumor microenvironment, counteracting the immunosuppressive conditions that melanomas establish through regulatory T cells, suppressive macrophages, and inhibitory signaling pathways. Additional plasmids support antigen presentation and local inflammation, ensuring that the tumor becomes visible to the immune system rather than remaining immunologically silent. By encoding several factors simultaneously on separate but co-delivered plasmids, the approach avoids the cargo-size constraints that limit many viral vectors and allows the relative composition of the mixture to be tuned, something that fixed viral constructs cannot easily achieve.

Technically, the delivery of plasmid DNA into cells in vivo is typically enhanced by electroporation, a process in which short electrical pulses are applied to the injected tissue to transiently permeabilize cell membranes, allowing DNA to enter. Intratumoral electroporation has been explored in multiple clinical trials of cancer gene therapy, and its safety profile has been well characterized: the procedure is minimally invasive, can be performed under local anesthesia for accessible lesions, and confines gene expression largely to the treated tissue. This spatial restriction is an important safety feature, because it limits systemic exposure to cytokines that, when delivered as recombinant proteins throughout the body, can cause severe toxicity. The authors of the new work built on this established foundation, refining both the genetic composition of the plasmid cocktail and the parameters of its administration to maximize expression levels and antitumor activity.

The reported outcome, high levels of metastatic melanoma regression, is significant for several reasons. First, regression extended beyond the directly injected lesions, indicating that the treatment did more than destroy the cells physically contacted by the needle. This systemic component is the essential requirement for any therapy intended to control metastatic disease, in which tumor deposits are scattered across the skin, lymph nodes, lungs, liver, brain, and other organs. Second, the magnitude of the response suggests that the plasmid combination achieved biologically meaningful expression levels, overcoming the historical weakness of non-viral delivery. Third, the strategy is modular: because plasmids are cheap and quick to produce under good manufacturing practice conditions, alternative gene combinations could in principle be swapped in for different tumor types or to overcome resistance mechanisms as they emerge.

The implications for combination therapy are particularly noteworthy. Current standards of care for advanced melanoma include anti-PD-1 antibodies, sometimes combined with anti-CTLA-4 blockade, and BRAF plus MEK inhibitors for patients whose tumors carry BRAF V600 mutations. Each of these approaches eventually encounters resistance. An intratumoral plasmid therapy that generates local inflammation and broad neoantigen-specific T cell priming could act synergistically with checkpoint inhibitors, which function by releasing the brakes on T cells that have already been activated. In this sense, plasmid-based intratumoral treatment addresses the ignition problem, priming and expanding antitumor immunity, while checkpoint blockade addresses the brake problem, sustaining that immunity once it exists. Clinical trials testing such rational combinations are a natural next step for the field, and the preclinical findings reported here provide the mechanistic justification for pursuing them.

Safety and manufacturability considerations also weigh in favor of the plasmid approach. DNA plasmids are non-infectious, do not integrate efficiently into the genome, and can be produced at scale in bacterial fermentation at costs far below those of engineered viral vectors or personalized neoantigen vaccines. For patients, intratumoral administration means that only lesions reachable by injection can be treated directly, which is a limitation for visceral disease, although the demonstrated abscopal effect means that even a single injected lesion can, in principle, drive immunity against distant deposits. The procedure also allows repeated dosing, since DNA expression is transient by design, and transient expression of potent immunostimulatory molecules is generally safer than continuous systemic exposure.

The study adds momentum to a broader revival of interest in non-viral gene delivery, a field currently energized by the success of lipid nanoparticles in RNA therapeutics. Plasmid DNA and RNA-based approaches differ in important ways, with plasmids offering nuclear delivery and potentially longer expression, and the present work demonstrates that, with the right construct design and delivery conditions, non-viral DNA can reach the expression levels required for robust therapeutic activity in cancer. For metastatic melanoma patients whose disease has stopped responding to approved immunotherapies, and for the clinicians caring for them, the prospect of a simple, reproducible, and manufacturable intratumoral treatment that recruits the immune system against the full antigenic breadth of their own tumor represents a meaningful and cautiously encouraging advance. Continued preclinical validation and, ultimately, controlled clinical testing will determine how this novel plasmid combination fits into the evolving treatment landscape of advanced melanoma.

Subject of Research: Intratumoral plasmid gene delivery for the treatment of metastatic melanoma

Article Title: Intratumor delivery of a novel plasmid combination induces high levels of metastatic melanoma regression

Article References: Heller, L. C., Singh, J. S., Synowiec, J. C., Jaroszeski, M. J., Otten, A., & Heller, R. (2026). Intratumor delivery of a novel plasmid combination induces high levels of metastatic melanoma regression. Gene Therapy. https://doi.org/10.1038/s41434-026-00644-y

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00644-y

Keywords: metastatic melanoma, plasmid DNA, intratumoral delivery, gene therapy, cancer immunotherapy, non-viral vectors, electroporation, antitumor immunity, abscopal effect, checkpoint inhibitors, tumor microenvironment, melanoma regression

TENGs were first reported in 2012 by Zhong Lin Wang and colleagues, and they work by exploiting a phenomenon most people regard as a nuisance: static electricity. When two materials with different electron affinities repeatedly contact and then separate, electrons transfer between them, leaving one surface positively charged and the other negatively charged. As the surfaces part, the accumulated charge creates a potential difference that drives electrons through an external circuit, producing usable electrical output. Wang later grounded the technology in theory by extending classical Maxwell’s equations through the concept of displacement current, showing that the time-dependent change in surface polarization acts as the primary driving force for induced current. Unlike conventional electromagnetic generators that rely on magnetic flux, TENGs generate current through dynamic electrostatic potential changes caused by periodic mechanical deformation, which makes them exceptionally good at harvesting low-frequency biomechanical energy such as walking, breathing, heartbeat or organ motion.

This output profile, high voltage combined with low current and pulsed waveforms, is precisely what makes TENGs attractive for oncology. Conventional electrical stimulation therapies require external power supplies, wired instrumentation and bulky equipment; electroporation systems use high-voltage pulses that risk collateral tissue damage; and tumor-treating fields, while clinically validated in selected malignancies, demand continuous device wear and carry high treatment costs. TENG systems, by contrast, are flexible, lightweight, biocompatible and entirely self-powered, drawing their energy from the body’s own movement. The devices operate in four fundamental modes: vertical contact-separation, single-electrode, linear sliding and freestanding triboelectric-layer configurations. Each mode shares the same underlying physics but differs in structure and motion pattern, giving engineers the flexibility to embed TENGs in wearables, implantables, smart textiles and self-powered environmental monitors.

One of the most striking applications described in the review is cancer prevention through environmental monitoring. Because most TENG platforms cannot yet detect tumor biomarkers directly, researchers have focused them on the carcinogenic exposures that precede malignancy. For respiratory cancer, the leading cause of cancer-related death worldwide, Wang and colleagues built a respiration-driven formaldehyde sensor using a titanium carbide MXene and ammonium-functionalized carbon nanotube triboelectric layer that detected the carcinogen at concentrations as low as 10 parts per billion, with response and recovery times of just 51 and 57 seconds. Yang and colleagues coupled a rotating TENG to a photocatalytic purification system, boosting formaldehyde degradation to 79.2 percent within 90 minutes, roughly 13 percent better than uncoupled systems. For benzene, Khandelwal and colleagues created a self-powered cellulose acetate and PVDF-titania sensor that achieved an 80 percent response at high concentrations and included a built-in alarm circuit requiring no external battery.

Particulate matter, another major lung cancer risk, has been tackled with triboelectric air filtration systems. Li and colleagues showed that a PTFE and polyester fiber-based filter raised short-term filtration efficiency from 36.7 percent to 74.6 percent and removed 99 percent of PM2.5 within 30 minutes, while Zheng and colleagues demonstrated a filter-free electrostatic purifier that used a TENG generating roughly 2 kilovolts to cut PM2.5 concentration in a test chamber from 954 to 50 micrograms per cubic meter in under 200 seconds, with minimal ozone production. For skin cancer, Zhang and colleagues developed a portable ultraviolet photodetector powered by a contact-separation TENG producing about 60 volts per cycle, and Cheng and colleagues wove TENG fibers into a multifunctional fabric offering an ultraviolet protection factor of 328, UV transmittance of only 0.21 percent, radiative cooling that kept the surface nearly 7 degrees Celsius cooler than cotton, and antibacterial inhibition rates above 98 percent against common pathogens.

The preventive reach of TENGs extends into the gastrointestinal tract, liver, colon and oral cavity. He and colleagues built an ethanol vapor sensor from a beta nickel hydroxide and MXene composite that detected exhaled ethanol below 200 parts per million with response and recovery times of 15 and 4 seconds even at 87 percent relative humidity, enabling battery-free screening for alcohol-related cancer risk. Cai and colleagues created a wood-based wireless gas sensor that detects ammonia released by spoiling food, a surrogate marker for aflatoxin, the well-known liver carcinogen, distinguishing clean air from 340 parts per million ammonia with recovery times under 11 seconds. Guo and colleagues went further, integrating a TENG producing roughly 380 volts with an electrowetting valve and a paper microfluidic device to automate enzyme-linked detection of alpha-fetoprotein, a hepatocellular carcinoma biomarker, completing the entire analysis in 260 seconds. Against Escherichia coli O157:H7, a microbe linked to colorectal cancer, Jin and colleagues’ rotating TENG powered ultraviolet lamps that reduced bacterial contamination on apple surfaces to 42 percent of original levels within an hour, while Luo and colleagues used a nine-thousand-volt TENG output to inactivate roughly 98 percent of E. coli and Staphylococcus aureus in water through electroporation.

On the therapeutic side, the review catalogues a series of remarkable preclinical results. Khayamian and colleagues developed a TENG-driven balloon catheter for irreversible electroporation of breast cancer tissue left behind after breast-conserving surgery; treated mice showed a 94 percent reduction in tumor volume within 15 days, whereas untreated controls saw tumors grow by 303 percent. Critically, irreversible electroporation induces immunogenic cell death, releasing tumor antigens and damage-associated molecular patterns that recruit dendritic cells and activate T cell responses, converting a local ablation into a systemic anticancer stimulus. Li and colleagues’ braided direct-current TENG, delivering 8,000 volts through stimulation needles inserted directly into tumors, shrank tumor mass by about 87 percent in mice within two weeks without damaging surrounding vessels. In the catalytic domain, Zhong and colleagues showed that TENG-generated electric fields modulate the d-band electrons of copper single-atom nanozymes, amplifying free radical production and oxidative tumor damage, while Yao and colleagues achieved an 83.6 percent tumor inhibition rate using electrical stimulation alone by boosting nanozyme catalytic activity fourfold and increasing current flow through conductive hydrogel injection.

Gas therapy and gene delivery round out the therapeutic arsenal. Yao and colleagues built a wearable stretchable TENG that wirelessly powers an implantable nitric oxide releasing device for glioma, increasing nitric oxide release by 183 percent compared with button cells and achieving at least 90.9 percent tumor inhibition over 14 days, with complete eradication in one case. Because nitric oxide above micromolar concentrations selectively kills cancer cells while sparing healthy tissue, and given its half-life of only a few minutes, such precision self-powered delivery is a significant advance. In gene therapy, Yang and colleagues demonstrated a TENG-driven nanowire electrode array that delivered siRNA to pancreatic cancer and leukemia cells in just 40 seconds, suppressing oncogene expression including KRAS and BCR-ABL while maintaining roughly 90 percent cell viability, with delivery efficiencies exceeding 95 percent in cells that are notoriously difficult to transfect. The team also paired an implantable magnetic TENG with doxorubicin-loaded red blood cells, using electroporation to trigger drug release at very low concentrations, and described ultrasound-activated Trojan nanogenerators combining electrical stimulation with catalytic therapy.

Perhaps most provocative is the emergence of triboelectric immunotherapy. Li and colleagues showed that a small fabric direct-current TENG, just 6.8 by 7 centimeters, could generate sufficient pulsed direct current to induce immunogenic cell death in tumor cells, driving dendritic cell maturation, T cell differentiation and durable antitumor immunity without any drug at all. The same group later combined this drug-free approach with CD19-targeted CAR-T cells against solid tumors, promoting M1 macrophage polarization, reducing regulatory T cells and enhancing CAR-T infiltration to eradicate nearly 60 percent of tumor mass, with the CAR-T cells differentiating into memory T cells that provided long-term protection against recurrence. The authors caution that substantial obstacles remain before clinical translation: long-term biocompatibility and degradation studies are needed, electrophysiological risks such as unintended cardiac or nerve stimulation must be rigorously controlled, and output variability across devices and patients demands standardized fabrication, calibration and dosing protocols. Still, if those challenges can be met, TENG technology could bridge environmental sensing, behavioral modification and preventive oncology into a single sustainable framework, transforming biomechanical energy itself into a tool against cancer.

Subject of Research: Triboelectric nanogenerators for cancer prevention, therapy and immunotherapy

Article Title: Triboelectric nanogenerators for cancer prevention and therapy: a new paradigm in cancer management

Article References: Dandugudumula, R., & Shin, D. Y. (2026). Triboelectric nanogenerators for cancer prevention and therapy: a new paradigm in cancer management. Advances in Industrial and Engineering Chemistry, 2(1), Article 8. https://doi.org/10.1007/s44405-026-00048-x

Image Credits: AI Generated

DOI: 10.1007/s44405-026-00048-x

Keywords: triboelectric nanogenerators, cancer therapy, energy harvesting, immunotherapy, drug delivery, electroporation, carcinogen monitoring, nanozymes, CAR-T cells, wearable sensors, implantable devices, nitric oxide therapy